The Medicines Co.’s Slimmer Cangrelor Filing Slated For April Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Company believes it has addressed all of FDA’s concerns in an April 2014 “complete response” letter relative to use during percutaneous coronary intervention, the only indication that will be the focus of a second advisory committee review.